Inflammation plays an important role in the destruction of pancreatic islet b-cells that leads to type I diabetes. This involves infiltration of T-cells and macrophages into the islets and local production of inflammatory cytokines such as interleukin (IL)-1b, tumor necrosis factor (TNF)-a, and interferon (IFN)-g. Our laboratory has developed several strategies for protecting b-cells against oxidative stress and cytokine-induced cytotoxicity. These include a cytokine selection strategy that results in cell lines that are resistant to the combined effects of IL-1b þ IFN-g. More recently, we have combined the cytokine selection procedure with overexpression of the antiapoptotic gene bcl-2, resulting in cell lines with greater resistance to oxidative stress and cytokine-induced damage than achieved with either procedure alone. This article summarizes this work and the remarkably divergent mechanisms by which protection is achieved in the different model systems. We also discuss the potential relevance of insights gained from these approaches for enhancing islet cell survival and function in both major forms of diabetes.
Introduction
Type I and type II diabetes are often thought of as diseases with completely distinct etiology. Thus, type I diabetes results from autoimmune destruction of insulin-producing pancreatic islet b-cells, while type II diabetes involves a constellation of metabolic disorders including insulin resistance, impaired control of hepatic glucose production, and b-cell dysfunction. A role for inflammatory mediators in the killing of b-cells in type I diabetes is clearly established. Destruction of b-cells results from direct contact with infiltrating T-cells and macrophages as well as exposure to inflammatory cytokines such as interferon (IFN)-g, interleukin (IL)-1b, tumor necrosis factor (TNF)-a, and reactive oxygen/nitrogen species (ROS/RNS) 1 that such cells produce. [1] [2] [3] [4] More recently, inflammatory mediators have become increasingly implicated in the development of type II diabetes. Key observations in support of this concept have included demonstration of a role for adipocyte-derived TNFa in the development of insulin resistance, 5 as well as studies
showing that anti-inflammatory agents such as aspirin or salicylate are able to prevent or reverse insulin resistance via an effect on Ik-ba and NF-kB activation. 6 Moreover, studies in rodent models of type II diabetes such as the ZDF rat demonstrate an early compensatory increase in b-cell mass as insulin resistance develops, followed by a loss of b-cell mass as insulin secretion declines and frank diabetes ensues. 7 That this loss of b-cell mass might be mediated by inflammatory agents is supported by studies in which lipid-laden islets of ZDF rats, or islets caused to store fat by chronic culture in fatty acids, are much more susceptible to cytokine-mediated cytotoxicity than islets from lean ZDF rats or normal islets cultured in the absence of fat, respectively. 8 It should also be noted that islets are thought to be more susceptible to damage from oxidative stress than other tissues due to their extremely low expression of oxygen radical metabolizing enzymes such as manganese superoxide dismutase (MnSOD), catalase, and glutathione peroxidase. These findings provide motivation for studies on the mechanisms by which inflammatory agents cause functional impairment and cytotoxicity in b-cells, and also spur the development of methods for protecting islet cells against such attack. In the current article, we summarize recent work from our laboratory in this area. Although our studies were originally carried out in the context of development of new cell-based therapies for type I diabetes, they may ultimately have relevance to b-cell dysfunction and deterioration in type II diabetes.
Development of methods for protecting insulinoma cell lines from cytokine-induced damage
The success of a recent human islet transplantation trial, involving administration of a mixture of nonsteroidal immunosuppressive drugs, has focused fresh attention on cell-based insulin replacement strategies for treatment of type I diabetes. 10 However, limited tissue supply and concerns about life-long administration of immunosuppressive agents may limit the applicability of this approach. We and others have therefore been investigating the potential utility of engineered cell lines as surrogates for primary islet cells in the treatment of type I diabetes. [11] [12] [13] [14] [15] We envision that such cells would be delivered in the context of a macroencapsulation device that will prevent contact of cellular elements of the immune system and the engrafted tissue. 12 However, immunoisolation barriers will not protect the cells from damage caused by soluble inflammatory mediators such as cytokines and ROS/RNS. Thus, a major goal of our group has been the development of cell lines that are resistant to both cytokine-and oxygen radical-induced damage.
As shown in Figure 1 , low concentrations of MnSOD, catalase, or glutathione peroxidase not only can lead to accumulation of hydrogen peroxide, hydroxyl radicals, and other ROS, but can also result in reaction of these radicals with other noxious agents, for example, the combination of superoxide dismutase with nitric oxide to generate the highly toxic radical peroxynitrite. 16 The rat insulinoma cell 20 However, in our studies,
MnSOD overexpression failed to provide any protection against the damaging effects of another inflammatory cytokine, IFN-g. 19 As immune attack on b-cells in type I diabetes is thought to involve a mixture of cytokines, including IFN-g, we shifted our focus toward development of a more comprehensive strategy for protection of cells against complex inflammatory insult. To this end, we developed a cytokine selection strategy, involving culture of INS-1 cells in the combined presence of IL-1b þ IFN-g 21 ( Figure 2 ). Cells were initially cultured in relatively low concentrations of these agents, resulting in killing of most, but not all, cells in the population. The surviving cells were recovered and then exposed to iteratively increasing concentrations of the cytokines, culminating in selection of a population of cells that could be grown in the presence of the very high cytokine levels (10 ng/ml IL-1b þ 100 U/ml IFN-g). We also tested the stability of the selection strategy by growth of cells in the absence of cytokine for 2 months after application of the selection procedure. Prior to cytokine selection, 85% of cells were killed by application of IL-1b þ IFN-g for 48 h. After exposure to the cytokine selection procedure, cells were essentially 100% resistant to cytokine damage. Withdrawal of cytokines for 2 months after completion of the selection procedure resulted in cells that retained most, but not all, of the cytokine resistance gained via the selection procedure. Further analysis of the effects of individual cytokines revealed that selected cells cultured in the absence of cytokines retain complete resistance against IL-1b-induced damage, but lose their resistance to IFN-g in the absence of cytokines in the medium. The resistance to IFN-g could be restored by re-culture with cytokines. 21 Mechanisms involved in cytokine resistance in selected cell lines
Having procured cell lines with resistance to multiple cytokines, we next investigated the mechanism by which this was achieved. Our initial approach was to examine known elements of the IL-1b and IFN-g signaling pathways in cytokine-sensitive and -resistant cell lines. IL-1b-mediated damage of islet cells is known to involve NF-kB-mediated increases in iNOS expression and production of nitric oxide (NO). [1] [2] [3] [4] We observed a complete blockade of NO production in our selected cell lines in response to acute incubation with IL-1b or conditioned media from mitogen-stimulated peripheral blood mononuclear cells (PBMC), whereas similar treatment of unselected cells resulted in large increases in NO production. 21 The block in NO production in selected cells was accompanied by a sharp decrease in the expression of inducible nitric oxide synthase (iNOS) and impairment in NF-kB activation as measured by EMSA analysis. The block in NF-kB appears to occur distal to degradation of its regulatory factor IkB, as this factor was degraded to a similar extent in selected and unselected cells in response to acute treatment with IL-1b (G Chen, CB Newgard, and X Chen, unpublished observations). Further investigation will be required to define fully the precise factors involved. A similar strategy was employed to gain insight into the mechanism of transient, re-inducible resistance to INF-g in selected cell lines. IFN-g signals by causing dimerization of the heterodimeric IFN-R receptor, leading to binding and activation of Jak kinase. Jak kinase then phosphorylates the receptor, enabling its binding to signal transducer and activator of transcription (STAT)-1a via its C-terminal SH2 domain. Juxtaposition of STAT-1a and Jak kinase results in phosphorylation of receptor-associated STAT-1a, rendering it competent for homo-or heterodimerization (eg, with other members of the STAT family of proteins), nuclear translocation, DNA binding, and activation of transcription. [22] [23] [24] Evaluation of the components of this pathway led to the observation that STAT-1a phosphorylation occurs normally in response to acute treatment with IFN-g or IFN-g þ IL-1b. However, STAT-1a expression was dramatically increased in response to the selection procedure. 25 That the increase in STAT-1a levels might be relevant to the IFN-g resistance induced by the selection procedure was supported by the finding that the increase in expression was observed only in cells that were grown in the continual presence of cytokines, and not in cells subjected to the selection procedure and grown in the absence of cytokines. Recall that cells grown under the latter conditions lose their IFN-g resistance. We also observed that while IL-b treatment of unselected cells was able to block IFN-g-induced STAT-1a expression, IL-1b failed to suppress IFN-g-mediated STAT-1a induction in selected, IL-1b-resistant cells. More direct evidence for a protective role of STAT-1a was then obtained by adenovirusmediated overexpression of the transcription factor in unselected INS-1 cells. This maneuver resulted in increased viability in INS-1 cells exposed to IL-1b alone, IFN-g alone, and IL-1b þ IFN-g. Unselected cells exposed to 10 ng/ml IL1b þ 100 U/ml IFN-g for 48 h were only 10% viable, while the same cells with overexpressed STAT-1a were 50% viable when exposed to the same high concentrations of the two cytokines. We concluded that induction of STAT-1a makes an important contribution to the IFN-g resistance conferred by our selection procedure. 25 Combined effects of an antiapoptotic gene and cytokine selection
More recently, we have had an opportunity to compare the protective effects of our cytokine selection procedure with those achieved by overexpression of the antiapoptotic gene bcl-2. Several laboratories have reported that bcl-2 expression provides partial protection against damage incurred by incubation with combinations of inflammatory cytokines. [26] [27] [28] Using bcl-2-expressing cells as a start point, one group has gone further and co-expressed several molecules that serve as dominant negative reagents for blockade of individual cytokine signaling pathways. 27, 29, 30 However, in this and all other cases, only partial resistance against damage incurred in the presence of a mixture of inflammatory cytokines has been achieved. Our group has prepared INS-1-derived cell lines with stable overexpression of bcl-2, allowing direct comparison of these cells with lines derived by the cytokine selection strategy. We found that bcl-2-overexpressing cells were highly resistant to the cytotoxic effects of ROS and RNS, but only modestly protected against high concentrations of IL-1b þ IFN-g, while the converse is true of INS-1-derived cell lines subjected to the cytokine selection procedure. 31 We also found that the combination of bcl-2 expression and cytokine selection confers a broader spectrum of resistance than either procedure alone, such that the resultant cells are highly resistant to incubation with high doses of cytokines or ROS/RNS. INS-1-derived cells with combined bcl-2 expression and cytokine selection were also more resistant to damage induced by co-culture with mitogen-activated PBMC. Surprisingly, application of the cytokine selection procedure to bcl-2-overexpressing cells did not result in impairment of NF-kB translocation, iNOS expression, or NO production, as clearly occurs upon application of the selection procedure to cells without bcl-2 overexpression. Thus, our cytokine selection procedure leads to resistance against cytokine-mediated cytotoxicity by distinct pathways dependent on the presence or absence of a background of bcl-2 expression. Table 1 provides a summary of the efficacy of strategies employed by our group for conferring protection against oxidative stress and cytokine-mediated cell damage.
Our working hypothesis to explain these results is as follows. We believe that cells lacking bcl-2 overexpression must reduce iNOS expression and NO production to attain cytokine resistance. This idea is supported by prior work showing that the iNOS inhibitor
is an effective blocker of NO production and IL-1b-mediated cytotoxicity, including in INS-1 cells. 3, 21 We further suggest that bcl-2-transfected cells subjected to the selection procedure can become cytokine resistant even in the absence of suppression of NF-kB translocation and NO production via activation of cytoprotective genes. Thus, in the initial weeks of the selection process, cells that lack bcl-2 expression avoid cytokine-induced damage by blocking production of NO via impairment of NF-kB translocation. Cells transfected with bcl-2, in contrast, maintain the ability to activate NF-kB in response to cytokines. This may be mediated by the BH4 domain of bcl-2, which has been suggested to cause degradation of Ik-Ba, thereby releasing NF-kB for nuclear translocation. [32] [33] [34] [35] Consistent with this model, we observed lower levels of Ik-Ba in our bcl-2-overexpressing, selected cell lines than in cells lacking bcl-2 expression and subjected to the selection procedure. 31 We suggest that chronic activation of NF-kB may lead to increased expression of genes with cytoprotective function such as Hsp27, Hsp70, and MnSOD. 36 Further studies will be required to fully develop these ideas.
Concluding remarks
In summary, work from our laboratory and others over the past several years has resulted in development of methods for protecting insulinoma cell lines from oxidative and cytokine-induced damage. Further work with these model systems leading to more detailed understanding of the diverse pathways by which cells can become resistant to cytokine and ROS/RNS may lead to development of simplified and specific strategies for immunoprotection of cells destined for transplantation therapy of diabetes. We believe that transplantation of expandable populations of human cells, whether they originate as stem cells or conditionally immortalized cell lines, will require the use of encapsulation membranes or devices to offset the tumorigenic potential of such cells. Such encapsulation devices will also prevent contact between cellular components of the immune system and the transplanted tissue. However, it is likely that transplantation of encapsulated allogeneic cells will induce at least a mild inflammatory response, especially in patients with autoimmune diabetes, that will require installation of additional protective features in the transplanted cells. The work described in this article may ultimately provide the appropriate tools for achieving this goal. The studies described herein may also have relevance for understanding the role of inflammation in b-cell dysfunction and damage in type II diabetes. Thus, lipid-laden islets from animal models of diabetes such as the ZDF rat, or normal islets chronically cultured in elevated concentrations of lipids exhibit increased rates of apoptosis and impairment of glucose-stimulated insulin secretion. 7, 8 Current studies in our laboratory are focused on determining if our selected INS-1 cell lines, with or without bcl-2 overexpression, exhibit resistance to either the apoptotic or functional effects induced by chronic exposure to lipids. If so, identification of specific molecular events that confer resistance to cytokine-induced and oxidative damage in the model systems described in this article could lead to identification of drug targets for enhancing b-cell function and survival in type II diabetes. 
